Keros Therapeutics Inc. shares lost over three-quarters of their market capitalization on Thursday, marking an all-time low, ...

A systematic review of quality-of-life tools available specifically for pulmonary arterial hypertension (PAH) reveals that ...

The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg ...

Keros Therapeutics has halted dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial ...

Aims Pulmonary hypertension (PHT) appears to be very common in heart failure with preserved ejection fraction but details on ...

Long-term exposure to high levels of air pollution can accelerate the progression of both chronic respiratory diseases and pulmonary hypertension.

门脉性肺动脉高压（portopulmonary hypertension，PoPH）是门静脉高压的一种常见并发症，目前被归为肺动脉高压（pulmonary arterial ...

Merck’s new pulmonary arterial hypertension (PAH) medication has posted another batch of promising clinical trial data, ...

The AIIMS Bhopal has achieved a significant milestone by successfully performing a rare and complex surgery to treat a 27-year-old patient diagnosed with Chronic Thromboembolic Pulmonary Artery ...